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Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We
conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients
whose tumours expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated
with 400mg of imatinib twice daily. One patient with metastatic acral lentiginous melanoma, containing the highest c-kit expression
among all patients, had dramatic improvement on positron emission tomographic scan at 6 weeks and had a partial response lasting
12.8 months. The responder had a substantial increase in tumour and endothelial cell apoptosis at 2 weeks of treatment. Imatinib was
fairly well tolerated: no patient required treatment discontinuation because of toxicity. Fatigue and oedema were the only grade 3 or
4 toxicities that occurred in more than 10% of the patients. Imatinib at the studied dose had minimal clinical efficacy as a single-agent
therapy for metastatic melanoma. However, based on the characteristics of the responding tumour in our study, clinical activity of
imatinib, specifically in patients with melanoma with certain c-kit aberrations, should be examined.
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Imatinib (STI-571, Gleevec; Novartis Pharmaceuticals, Basel,
Switzerland) is a small-molecule inhibitor of protein tyrosine
kinases (PTKs), including the Bcr–Abl fusion protein, c-abl, abl-
related gene (ARG), platelet-derived growth factor receptor
(PDGFR)-a, PDGFR-b, and the c-kit tyrosine kinase receptor
(Druker and Lydon, 2000; Schindler et al, 2000; Okuda et al, 2001).
In cell-based assays, imatinib selectively inhibits PDGF- and stem
cell factor-mediated cellular signalling, including ligand-stimulated
receptor autophosphorylation, inositol phosphate formation, and
mitogen-activated protein kinase activation and proliferation
(Buchdunger et al, 1995, 1996). These properties suggest that in
addition to treating chronic myelogenous leukaemia and gastro-
intestinal stromal tumours, imatinib may be useful in the
treatment of diseases that involve abnormal activation of c-kit,
PDGFRs, or other PTKs.
We previously demonstrated differential expression of PTKs in
paraffin-embedded human metastatic melanoma specimens (Shen
et al, 2003). Out of 31 specimens examined by immunohistochem-
istry (IHC), 17 (55%) expressed c-kit, 30 (97%) expressed PDGFR-
a, 21 (68%) expressed PDGFR-b, 23 (74%) expressed ARG, and 27
(87%) expressed c-abl. These findings indicate that a subset of
patients with metastatic melanoma may have tumours that express
imatinib’s target PTKs. To evaluate the clinical efficacy of imatinib
in patients with metastatic melanoma that expressed these PTKs,
we conducted a phase II study of imatinib. We performed tumour
biopsies before and during treatment to examine genetic muta-
tions and PTK expression and to assess the effects of imatinib on
apoptosis of tumour and tumour-associated endothelial cells.
MATERIALS AND METHODS
Patient selection
This was an open-label, phase II clinical trial. The protocol for this
study was approved by the Institutional Review Board of The
University of Texas M.D. Anderson Cancer Center. All patients
gave written informed consent before enrollment.
Eligible patients were required to have histologically confirmed
melanoma with measurable metastases and no more than one
prior systemic treatment, not counting adjuvant interferon-a.A
pretreatment tumour biopsy must have had at least 25% of the
tumour cells stain positive by IHC for PDGFR-a, PDGFR-b, c-kit
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s(CD117), c-abl, or ARG for patients to enroll in this trial. Patients
in whom the brain was the only site of metastasis or patients who
had symptomatic central nervous system metastases were ex-
cluded. However, patients with small asymptomatic brain metas-
tases were eligible.
Treatment plan
Imatinib was administered orally at a dose of 400mg twice a day
until there was evidence of disease progression or unacceptable
toxicity or until the patient refused to continue treatment. Because
imatinib can irritate the gastrointestinal tract, patients were
instructed to take the drug with meals. One course was defined
as 6 weeks of treatment. All patients underwent tumour biopsies
before treatment to assess target PTK expression by IHC. Patients
were also asked to undergo a second biopsy during the second
week of treatment for correlative studies.
Response evaluation
In addition to routine radiological assessment including computed
tomography at intervals of 6 weeks, patients’ disease was also
evaluated by positron emission tomography (PET) at baseline and
after 6 weeks of treatment. Clinical responses were evaluated using
the international criteria proposed by the Response Evaluation
Criteria in Solid Tumors Committee (Therasse et al, 2000).
Responses were evaluated after every 6-week course. Overall
clinical response included both complete and partial responses.
Time to progression, duration of response, and overall survival
were measured from the start of treatment.
Toxicity evaluation
Toxicities were evaluated and recorded according to the National
Cancer Institute’s Common Toxicity Criteria version 3.0. Patients
were required to keep a daily record of adverse events and changes
in concomitant medications. Complete blood counts and serum
chemistry panels were obtained every 2 weeks.
Receptor kinase expression
Immunohistochemical staining protocols were used to detect c-kit,
c-abl, ARG, PDGFR-a, and PDGFR-b in paraffin-embedded
tumour specimens (Shen et al, 2003). A rabbit antihuman antibody
against c-kit (dilution, 1ngml
 1) was purchased from DAKO
(Carpinteria, CA, USA); the rabbit (PDGFR-a, PDGFR-b) and goat
(c-abl) anti-human antibodies against PDGFR-a, PDGFR-b (dilu-
tions, 1ngml
 1), c-abl (dilutions 1:200), and ARG (dilutions
1:200) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Antibody staining was optimised using tissue sections
before antibodies were applied to tissue microarray sections.
PDGFR-a and PDGFR-b were retrieved by treatment with pepsin at
371C for 10min, c-kit was retrieved by microwave treatment for
5min, and no antigen retrieval was performed for c-abl or ARG.
All primary antibodies were applied to the slides and incubated at
41C overnight. Diaminobenzidine was used as a chromogen. Both
the percentage of positive cells and the intensity of staining were
graded by two dermatopathologists. The scoring system for IHC
staining for the PTKs was assigned in the following way. For the
percentage of cells staining positively for PTK: 0, 0–5%; 1, 6–25%;
2, 26–75%; 3, 475%; for the intensity of staining: 1, weak; 2,
moderate; 3, strong.
Tumour and endothelial cell apoptosis
Frozen tumour specimens were serially sectioned and stained for
vessel count with an immunofluorescent antibody against the
endothelial marker CD31. Apoptosis of tumour and endothelial
cells was assessed by counting the number of cells (out of a total of
500) that stained positively with terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling (TUNEL). Sections
were superimposed on one another by computer imaging to
determine the degree of endothelial cell apoptosis at the invasive
edges of the tumours.
DNA sequencing
DNA was isolated from frozen tissue or from tissue stored in
RNAlater (Ambion, Austin, TX, USA) using a QIAamp DNA
minikit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. RNA was extracted by standard methods using
an RNeasy minicolumn (Qiagen) according to the manufacturer’s
instructions. cDNA was prepared using the two-step TaqMan
reverse transcription reagent (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions, except that a
primer specific for c-kit RNA (KIT 2961R, 50-TTCCTGGAGGGGTG
ACCCAAACACT-30) was used instead of random primers. The
cDNA was then amplified by polymerase chain reaction. Nucleo-
tide sequences were analysed with a 3730 1 DNA analyser
(Applied Biosystems) at the M.D. Anderson Nucleic Acid Core
Facility. The genomic DNA sequence of exons 9, 11, 13, 15, and,
17 was analysed as described previously (Chen et al, 2004).
Statistical analysis
The statistical design of the study was based on a modified two-
stage Simon’s design (Simon, 1989). Twenty-one patients were to
be enrolled and treated in the first stage of the study and 20 in the
second stage, summing up to 41 patients. If the response rate was
5% (1 out of 21 patients) or less at the end of the first stage, the
study would be terminated. If two or more patients responded,
accrual would continue to a total of 41 patients. If the response rate
at the end of the study was 10% (4 out of 41) or less, the regimen
would be rejected for further study as a single agent for metastatic
melanoma. If the response rate was higher, the drug would be
recommended for further study. These calculations assumed there
was 90% or greater probability that the regimen would be
recommended for further study if the true efficacy rate was 20%
or greater, and less than 5% probability if the true efficacy rate was
5% or less.
RESULTS
Patient characteristics
From January 2002 to October 2003, 22 patients were enrolled and
21 were treated with imatinib. One patient with early progressive
central nervous system metastases was not treated. The pretreat-
ment characteristics of the patients are listed in Table 1. All 21
patients were evaluable for response and toxicity. Two patients
(10%) had stage III melanoma with multiple unresectable
in-transit lesions, and all others (90%) had stage IV melanoma.
All 22 patients enrolled had tumours expressing at least one
target PTK. The baseline immunohistochemical data for the
21 treated patients who qualified the patients for enrollment are
summarised in Table 2.
Treatment
The 21 patients received a total of 33 courses of imatinib (median,
one course per patient; range, 1–9). Three patients were unable to
complete the first course of therapy because of rapid disease
progression; one of them died of a progressing haemorrhagic brain
metastasis. Thirteen and four patients completed one and two
courses, respectively. The sole patient with responding disease
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1 year. One patient with a history of rheumatoid arthritis required
a dose reduction to 300mg twice a day because of grade 3
polyarthritis. No other patient required a dose reduction.
Responses
Clinical responses are listed in Table 2. Among the 21 patients
treated, 4 had disease stabilisation, which lasted no more than 12
weeks. Only one patient (5%) had a partial response, which lasted
for 12.8 months. That patient was a 66-year-old man whose disease
had progressed while he had been receiving intratumoral HLA-B7
plasmid gene transfer treatment. He had a near-complete response
to imatinib in numerous metastases of the cutaneous and
subcutaneous tissues, inguinal and iliac lymph nodes, and lungs.
Table 2 Receptor expression and clinical response
Patient c-kit PDGFR-a PDGFR-b c-abl ARG Response
(A) Pretreatment
1 3/2 0/0 2/1 0/0 0/0 PD
2 3/2 3/1 3/1 3/2 0/0 SD
3 0/0 0/0 3/1 2/1 0/0 SD
4 3/2 0/0 0/0 0/0 1/1 PD
5 3/1 0/0 3/1 0/0 0/1 PD
6 3/2 0/0 0/0 0/0 2/1 SD
7 3/2 3/2 3/2 3/1 0/0 PD
8 3/3 0/0 3/1 2/2 0/0 PR
9 3/2 3/2 3/3 3/2 2/1 PD
10 2/1 2/1 0/0 2/1 0/0 PD
11 2/2 0/1 0/1 2/3 2/3 PD
12 1/1 0/1 1/1 1/1 2/2 PD
13 3/2 0/0 1/1 2/1 1/1 PD
14 3/1 3/1 3/1 3/3 3/2 PD
15 3/2 2/1 2/1 2/1 0/0 PD
16 3/1 0/1 0/1 1/1 0/0 PD
17 2/2 2/1 3/1 2/2 1/1 PD
18 3/2 3/2 3/2 3/2 3/2 PD
19 2/1 3/3 2/1 1/1 0/0 SD
20 2/1 2/1 2/1 0/0 1/1 PD
21 0/0 2/1 1/1 2/1 0/0 PD
Patient c-kit PDGFR-a PDGFR-b c-abl ARG Response
(B) During second week of treatment
1 2/1k 0/0– 0/0k 2/1m 0/0– PD
2S D
3 0/0– 0/0– 0/0k 2/2m 2/1m SD
4 3/2– 0/0– 0/0– 0/0– 0/0k PD
5P D
6 3/2– 0/0– 0/0– 2/1m 2/1– SD
7P D
8 3/3– 0/0– 0/0k 0/0k 0/0– PR
2/2* 0/0* 0/0* 0/0* 0/0*
9 0/0k 1/1k 1/1k 1/1k 0/0k PD
10 2/2m 1/1k 0/0– 2/1– 0/0– PD
11 3/2m 0/2m 2/1m 2/1k 3/1– PD
12 2/2m 0/1– 3/2m 0/0k 1/1k PD
13 0/0k 0/1m 0/0k 0/0k 0/1k PD
14 PD
15 PD
16 PD
17 PD
18 1/1k 0/0k 0/0k 0/1k 0/1k PD
19 0/0k 0/0k 0/0k 0/0k 0/0– SD
20 PD
21 1/1m 1/2– 0/1k 2/1– 0/0– PD
ARG¼abl-related gene; PD¼progressive disease; PDGFR¼platelet-derived
growth factor receptor; PR¼partial response; SD¼stable disease. The first number
is an indicator of the percentage of cells staining positive for the protein tyrosine
kinase (PTK) (0, 0–5%; 1, 6–25%; 2, 26–75%; 3, 475%); the second number
denotes the staining intensity (1, weak; 2, moderate; 3, strong). Blank spaces indicate
no tissue available for analysis. m denotes increase in protein expression during
treatment. k denotes decrease in protein expression during treatment. – denotes no
change in protein expression during treatment. * denotes PTK expression at the time
of relapse (patient 8).
Table 1 Patient characteristics
Characteristic No. of patients (%)
Total patients enrolled for the study 22
Total patients treated 21
Evaluable patients 21 (100)
Sex
Male 13 (62)
Female 8 (38)
Age (years)
Median 58
Range 33–83
ECOG performance status
0 6 (29)
1 14 (67)
2 1 (5)
Disease stage
III 2 (10)
IV 19 (90)
(M1a) 2 (10)
(M1b) 6 (29)
(M1c) 11 (52)
Serum lactate dehydrogenase level
Normal 18 (86)
Higher than upper limit of normal 3 (14)
Prior treatment
None 8 (38)
Interferon-a therapy (adjuvant) 8 (38)
Isolated limb perfusion 2 (10)
Biologic 2 (10)
Chemotherapy 4 (19)
Pathologic type of primary melanoma
Superficial spreading melanoma 5 (24)
Nodular melanoma 2 (10)
Acral lentiginous melanoma 2 (10)
Melanoma of the soft part 1 (5)
Unknown primary 3 (14)
Unclassified or unspecified 8 (38)
Site of primary melanoma
Upper extremities 3 (14)
Thumb – terminal phalanx 1 (5)
Lower extremities 9 (43)
Plantar surface 5 (24)
Scalp/face/neck 2 (10)
Torso 4 (19)
Unknown 3 (14)
Site of metastases
Dermis/subcutaneous tissue 17 (81)
Lymph nodes 10 (48)
Lung 14 (67)
Liver 3 (14)
Bone 3 (14)
Brain 3 (14)
Number of organs with metastases
Median 3
Range 1–5
ECOG¼Eastern Cooperative Oncology Group.
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sAfter just 6 weeks of treatment, a PET scan revealed a marked
reduction of metabolic activity in all disease sites (Figure 1).
Follow-up computed tomography (CT) scans did not confirm
ongoing major response in this patient until after 12 weeks of
treatment. Serial physical exams with photographs confirmed
gradual depigmentation and complete resolution of all palpable
skin nodules and follow-up CT scans showed near-complete
resolution in nodal and lung metastases after 6 months. The
treatment was discontinued when he developed new brain
metastases and a recurrence in the lymph nodes. This patient
was later treated with temozolomide and paclitaxel achieving a
brief partial response, but subsequently died of disease progres-
sion 26 months after the beginning of imatinib treatment.
With progression of disease confirmed in all patients, the
median time to disease progression was 1.4 months (range,
0.6–12.8), and the median overall survival duration was 7.5
months (range, 0.7–25.8þ), with two patients alive at 19 months.
Toxicity
Adverse events are listed in Table 3 by toxicity grade and
frequency. No patient required treatment discontinuation for
toxicity. Fatigue and oedema were the only grade 3 or 4 adverse
events that occurred in more than 10% of the patients, and these
were reversible upon discontinuation of treatment.
Correlative studies
We examined PTK expression in melanoma cells at baseline
and during the second week of treatment (Table 2). Among the
21 patients treated, all with evaluable baseline tumour specimens,
16 also had specimens obtained during the second week of
treatment. Thirteen of the second-week specimens were evaluable
for PTK expression. With only one major response, no definite
association could be made between the baseline immunohisto-
chemical data and the observed clinical activity (Table 2A).
Nevertheless, the patient with the major response had strong c-kit
receptor staining in over 75% of the tumour cells – the strongest
staining pattern observed among all the pretreatment specimens.
Among the evaluable 13 paired baseline and follow-up speci-
mens, there were no consistent staining pattern changes observed
after 2 weeks of treatment. Most often, however, there was a
decrease in PTK receptor staining intensity (Table 2B). In the
patient with the major response, c-kit receptor staining did not
change, and there was complete loss of PDGFR-b and abl staining
2 weeks into treatment.
At baseline
Post 12 weeks of treatment
Post 18 weeks of treatment
Post 18 weeks of treatment
Post 6 weeks of treatment
At baseline
Lossy Image Lossy Image
Lossy Image Lossy Image
At baseline Post 6 weeks of treatment
Figure 1 Clinical and radiological studies of a partial response to imatinib. All metastatic lesions shrank. (A) Response of in-transit metastases on right
thigh. (B) Computed tomographic scan showing response of left external iliac lymph node (arrow). (C) Positron emission tomographic scans showing
decrease in fluorodeoxyglucose uptake in all lesions (arrows). (D) Photomicrograph of the strong c-kit expression in the tumour of the responder. (E)
Photomicrograph of a case of negative c-kit expression.
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sThe responding patient’s tumours also showed an increase in
the percentage of apoptotic endothelial and tumour cells after only
2 weeks of imatinib treatment, based on the CD31-TUNEL dual
immunofluorescence studies, suggesting a very early impact of
treatment on the tumour specimen (Figure 2).
We analysed pretreatment tumour samples from five patients,
including the only responder, for c-kit mutation for both genomic
DNA and cDNAs. None of our melanoma specimens analysed,
including those from the responding patient, contained genomic
mutations of c-kit in exon 9 or 11, which is frequently mutated in
imatinib-responsive gastrointestinal stromal tumours (Heinrich
et al, 2003). Genomic sequences of c-kit in exons 13, 15, and 17
were also analysed, and none of the specimens contained
mutations in these sites. Of interest, the cDNA to RNA from the
responder’s tumour displayed alternative splicing in exon 15 of
the c-kit kinase II domain (Figure 3). This alternate splice form
had a 3bp deletion of the codon for serine (codon 715) at the
very beginning of exon 15. The alternate splice form encodes the
SER
715  isoform of c-kit (Crosier et al, 1993; Lasota et al, 2002).
However, this finding was not specific for the responding patient;
four non-responding patients also had this alternative splice in
their tumours.
There was no evidence of an immunological infiltrate in the
responding metastases.
DISCUSSION
In this trial, imatinib was given orally at 400mg twice a day
without interruption. Wyman et al (2006) reported that imatinib
administered at 400mg twice a day caused unexpectedly severe
toxicity with frequent grade 3 or 4 adverse events, requiring dose
reduction and even treatment cessation. In another phase II study
of imatinib, in which 18 patients with treatment-refractory
advance melanoma were treated, Ugurel et al (2005) showed that
there was no clinical response among 16 evaluable patients.
However, in our study, 400mg of imatinib given twice a day was
fairly well tolerated. The toxicity of imatinib observed in our study
was similar to previously reported clinical studies (van Oosterom
et al, 2001; Verweij et al, 2003). Most adverse events, especially
skin rash and pleural effusion, were self-limiting without drug
discontinuation.
In our study, there was early progression of disease in the
majority of patients and only one partial response, precluding the
study from entering the second stage of accrual. This lack of
efficacy was also observed in the other clinical trial testing the
same dose and schedule of imatinib (Wyman et al, 2006). In that
trial, the 26 patients enrolled with metastatic melanoma had a
higher percentage of visceral metastases (stage M1c) and had
received more prior systemic therapy compared with the patients
enrolled in our study (58 vs 32% and 73 vs 27%, respectively).
More grade 3 or 4 nausea, vomiting, fatigue, fluid retention with
oedema, anaemia, hyponatraemia, and hypoglycaemia were
observed in the second trial, perhaps as a result of these poorer
prognostic characteristics. No clinical responses were reported.
Hence, there has been only one partial response reported among
the 46 evaluable patients treated in these two trials for an aggregate
response rate of 2% and a median time to progression of less than
8 weeks.
Since all tumours screened in our study expressed at least one of
the five target PTKs, based on positive immunohistochemical
staining in at least 25% of the cells, the 25% threshold was not
selective for predicting clinical response. Furthermore, there was
only one clinical response among the 21 patients; therefore,
positive IHC results, as defined in our study, were not predictive of
response to imatinib. Nevertheless, in tumours from the one
patient who had a meaningful and prolonged clinical response,
over 75% of the cells had marked c-kit staining. None of the other
patients’ tumours had such intense staining; thus the threshold for
positive staining, if used to select patients for treatment, could be
set at a higher value in future studies. On the other hand, no
change in the strong c-kit staining during the second week of
treatment in the responding melanoma could be evidence that total
expression of c-kit is not the critical marker for imatinib activity.
Similarly, the decrease in staining intensity for PDGFR-b and c-abl
in the responding tumour could be discounted as important leads
as this pattern of staining was also seen in the non-responding
specimens.
Despite the lack of correlative biological changes observed with
imatinib in this patient, we believe that the lone response was not a
coincidence because the response was observed in multiple sites
including multiple in-transit lesions, deep inguinal nodes, and
lung, and lasted more than a year on therapy. In addition, it is
worth noting that the responder’s primary disease was acral
lentiginous melanoma. Recently, Curtin et al (2006) demonstrated
that nearly 30–40% subtypes of melanoma, such as acral
lentiginous, mucosal melanoma, or cutaneous melanoma, on
chronic sun-damaged skin, harbour c-kit mutation and/or
aberration, such as a gene amplification or an increased gene
copy number. Although no genomic mutation in c-kit was found in
the tumour of the responder in our trial, it is possible that the
tumour contained either an increased c-kit gene copy number or
its gene amplification, which might have activated the c-kit signal
pathway. We found the alternative splice in exon 15, which
encodes the SER
715  isoform of c-kit in tumour samples, but this
variant, which has been reported in other tumour types by a
number of investigators (Crosier et al, 1993; Ashman, 1999; Lasota
et al, 2002), did not predict the response to imatinib.
The increase in apoptosis of both tumour and endothelial cells
in the responding patient implies that imatinib may effectively
inactivate important signal transduction pathways in endothelial
cells as well. For instance, PDGFRs are known to be expressed both
on melanoma and on endothelial cells (Beitz et al, 1991; Barnhill
et al, 1996; Shen et al, 2003). The nature of the imatinib-sensitive
signals that mediate survival of endothelial cells is being
Table 3 Toxicities observed with imatinib treatment (number of
patients with toxicity)
Adverse event Grade 1/2 Grade 3 Grade 4
Fatigue 14 3 1
Anaemia 12 — 1
Oedema 13 3 —
Nausea 13 2 —
Muscle weakness 6 2 —
Anorexia 14 1 —
Lymphopoenia 10 1 —
Vomiting 9 1 —
Skin erythema/pruritis 9 1 —
Constipation 7 1 —
Dyspepsia 7 1 —
Neutropoenia 4 1 —
Ocular effects (visual changes) 8 — —
Arthralgia 1 1 —
Dyspnoea 7 — —
Diarrhoea 7 — —
Pleural effusion 7
Diaphoresis 6 — —
Cough 6 — —
Haemorrhage 6 — —
Thrombocytopoenia 3 — —
Fever 3 — —
Serum creatinine elevation 3 — —
Peripheral neuropathy 2 — —
Petechia 2 — —
Ascites 1 — —
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sinvestigated. We are currently investigating the phosphorylation
status of the target PTKs and the effect of imatinib on the
inactivation of these targets in melanoma and endothelial cells of
tumours from the patients in this study.
As reported in CML and GIST, resistance to imatinib was
observed in the responder after 1 year of treatment. Many mecha-
nisms have been suggested for this as well as ways to circumvent
evolution of resistance in a previously exploitable pathway,
including, but not limited to, substituting other PTK inhibitors
or combining imatinib with other agents that affect other signal
transduction steps. In addition, imatinib resistance might result
from kinase-activating mutations of B-Raf, which is downstream of
the target receptor kinases of imatinib. Davies et al (2002) recently
showed that approximately 66% of melanomas contain somatic
missense mutations, located within the kinase domain of B-Raf,
with the ability to transform NIH3T3 cells. These mutations can
constitutively activate the mitogen-activated protein kinase path-
way, regardless of imatinib’s ability to inactivate upstream
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Figure 2 Tumour and endothelial cell apoptosis before treatment and during the second week of imatinib treatment. (A) Tumour cell apoptosis in five
patients; patient 5 had a partial response. (B) Endothelial cell apoptosis in five patients. (C) Photomicrographs of the TUNEL stains for both melanoma and
endothelial cells in the responder. Red in the CD31 column represents the endothelial cells, and green in the TUNEL column represents apoptotic cells.
Yellow (indicated by an arrow) in the overlay column represents endothelial cells undergoing apoptosis.
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Figure 3 Chromatogram of the sequence for the alternative splicing seen in c-kit mRNA from the responding patient. The c-kit cDNA sequence from the
responder displayed a deletion of the first three nucleotides of exon 15, which encoded a serine (codon 715).
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sreceptor kinases. It may be necessary to select patients without
such B-Raf mutations to increase the rate of clinical response to
imatinib in patients with metastatic melanoma.
There is also increasing evidence that combinations of imatinib
and chemotherapeutic agents, such as taxane or gemcitabine, have
synergistic antitumour activity in vitro and in vivo (Pietras et al,
2002; Hwang et al, 2003; Mathew et al, 2004).
In conclusion, single-agent imatinib had only minimal clinical
efficacy in patients with metastatic melanoma. The success of
imatinib as a targeted therapy for advanced melanoma will depend
on more stringent selection of patients with exploitable tumour
targets and its use either sequentially or in combination with other
agents. Currently, imatinib is under clinical investigation in
patients with advanced melanoma harbouring somatic alterations
of c-kit, and its result is eagerly anticipated.
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